The Impact of Prognostic Factors on Survival in Patients with Non-Metastatic Invasive Breast Cancer: A Single-Center Experience
Abstract
Background: Breast cancer (BC) is the most prevalent and lethal cancer in women. Prognostic factors are used to guide treatment and predict the prognosis. This study aims to assess the influence of prognostic factors on the survival of patients with non-metastatic invasive BC.
Methods: Data from invasive BC patients admitted to Medical Oncology Department of Süleyman Demirel University between October 2002 and October 2013 were retrospectively reviewed. Clinicopathologic features, treatment information, and follow-up data were noted. The Kaplan-Meier method was used to estimate survival functions. Multivariate Cox regression analysis was performed to identify prognostic factors for disease-free survival (DFS) and overall survival (OS), with p values <0.05 for univariate results
Results: A total of 717 patients entered the study. The median follow-up time was 41 months. Recurrence was detected in 17.4% of the patients, and 111 (15.5%) patients died. The 5- and 10-year DFS rates were 78% and 61%; OS rates were 86% and 70%, respectively. In multivariate analyses, DFS and OS were associated with axillary lymph node involvement (P<0.001 and P<0.05, respectively), tumor size (P<0.05), and histologic grade (P<0.05); whereas human epidermal growth factor receptor 2 positivity had only a statistically significant effect on poor OS (P=0.004).
Conclusion: Comparable to previous studies, traditional prognostic factors had an important impact on prognosis in invasive BC patients. In the current era, where more conservative surgical approaches and new, effective systemic neoadjuvant and adjuvant therapies are widely used, the importance of the traditional prognostic factors highlighted in our study needs to be established by further studies.
Full text article
References
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. DOI: 10.3322/caac.21660
Turkish Cancer Statistics by Republic of Turkey, Ministry of Health. Available: https://hsgm.saglik.gov.tr/depo/birimler/kanserdb/Dokumanlar/Istatistikler/Turkiye_Kanser_Istatistikleri_2017_OZETLI.pdf
Cao SS, Lu CT. Recent perspectives of breast cancer prognosis and predictive factors (Review). Oncol Lett. 2016;12(5):3674-8. DOI: 10.3892/ol.2016.5149
Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist. 2004;9(6):606-16. DOI: 10.1634/theoncologist.9-6-606
Nicolini A, Ferrari P, Duffy MJ. Prognostic and predictive biomarkers in breast cancer: Past, present and future. Semin Cancer Biol. 2018;52:56-73. DOI: 10.1016/j.semcancer.2017.08.010
Zorlutuna Ş. Survival Rate and Prognostic Factors in Turkish Women Patients with Breast Cancer. Iran J Public Health. 2022;51(2):375-85. DOI: 10.18502/ijph.v51i2.8690
Dağlar G, Yüksek YN, Gözalan AU, Tütüncü T, Güngör Y, Kama NA. The prognostic value of histological grade in the outcome of patients with invasive breast cancer. Turk J Med Sci. 2010;40(1):7-15. DOI: 10.3906/sag-0811-36
Gokce T, Karadogan I, Akcay C. A long-term survival pattern for breast cancer treated in a single institution. Indian J Cancer. 2011;48(2):187-93. DOI: 10.4103/0019-509x.82884
Özmen V. Breast Cancer in Turkey: Clinical and Histopathological Characteristics (Analysis of 13.240 Patients). J Breast Health. 2014;10(2):98-105. DOI: 10.5152/tjbh.2014.1988
Coughlin SS, Ekwueme DU. Breast cancer as a global health concern. Cancer Epidemiol. 2009;33(5):315-8. DOI: 10.1016/j.canep.2009.10.003
Özmen V, Özmen T, Doğru V. Breast Cancer in Turkey; An Analysis of 20.000 Patients with Breast Cancer. Eur J Breast Health. 2019;15(3):141-6. DOI: 10.5152/ejbh.2019.4890
Hayes DF, Trock B, Harris AL. Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful? Breast Cancer Res Treat. 1998;52(1-3):305-19. DOI: 10.1023/a:1006197805041
El Saghir NS, Seoud M, Khalil MK, et al. Effects of young age at presentation on survival in breast cancer. BMC Cancer. 2006;6(1):194. DOI: 10.1186/1471-2407-6-194
Kataoka A, Iwamoto T, Tokunaga E, et al. Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry. Breast Cancer Res Treat. 2016;160(1):163-72. DOI: 10.1007/s10549-016-3984-8
Rapiti E, Fioretta G, Verkooijen HM, et al. Survival of young and older breast cancer patients in Geneva from 1990 to 2001. Eur J Cancer. 2005;41(10):1446-52. DOI: 10.1016/j.ejca.2005.02.029
Kheirelseid EAH, Boggs JME, Curran C, et al. Younger age as a prognostic indicator in breast cancer: A cohort study. BMC Cancer. 2011;11(1):383. DOI: 10.1186/1471-2407-11-383
Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH, El Saghir NS. Epidemiology and prognosis of breast cancer in young women. J Thorac Dis. 2013;5 Suppl 1(Suppl 1):S2-8. DOI: 10.3978/j.issn.2072-1439.2013.05.24
Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004;6(3):R149. DOI: 10.1186/bcr767
Kwast ABG, Groothuis-Oudshoorn KCGM, Grandjean I, et al. Histological type is not an independent prognostic factor for the risk pattern of breast cancer recurrences. Breast Cancer Res Treat. 2012;135(1):271-80. DOI: 10.1007/s10549-012-2160-z
Wasif N, Maggard MA, Ko CY, Giuliano AE. Invasive lobular vs. ductal breast cancer: a stage-matched comparison of outcomes. Ann Surg Oncol. 2010;17(7):1862-9. DOI: 10.1245/s10434-010-0953-z
Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63(1):181-7. DOI: 10.1002/1097-0142(19890101)63:1<181::aid-cncr2820630129>3.0.co;2-h
Fisher B, Bauer M, Wickerham DL, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer. 1983;52(9):1551-7. DOI: 10.1002/1097-0142(19831101)52:9<1551::aid-cncr2820520902>3.0.co;2-3
Narod SA. Tumour size predicts long-term survival among women with lymph node-positive breast cancer. Curr Oncol. 2012;19(5):249-53. DOI: 10.3747/co.19.1043
Saadatmand S, Bretveld R, Siesling S, Tilanus-Linthorst MMA. Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173 797 patients. BMJ. 2015;351:h4901. DOI: 10.1136/bmj.h4901
Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. C. W. Elston & I. O. Ellis. Histopathology 1991; 19; 403-410. Histopathology. 2002;41(3a):151-2, discussion 2-3.
Warwick J, Tabàr L, Vitak B, Duffy SW. Time-dependent effects on survival in breast carcinoma: results of 20 years of follow-up from the Swedish Two-County Study. Cancer. 2004;100(7):1331-6. DOI: 10.1002/cncr.20140
Schwartz AM, Henson DE, Chen D, Rajamarthandan S. Histologic Grade Remains a Prognostic Factor for Breast Cancer Regardless of the Number of Positive Lymph Nodes and Tumor Size: A Study of 161 708 Cases of Breast Cancer From the SEER Program. Arch Path Lab. 2014;138(8):1048-52. DOI: 10.5858/arpa.2013-0435-OA
Zhong Y, Ding B, Qian L, Wu W, Wen Y. Hormone Receptor Expression on Endocrine Therapy in Patients with Breast Cancer: A Meta-Analysis. Am Surg. 2022;88(1):48-57. DOI: 10.1177/0003134820972327
Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007;9(1):R6. DOI: 10.1186/bcr1639
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-82. DOI: 10.1126/science.3798106
Borg A, Tandon AK, Sigurdsson H, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res. 1990;50(14):4332-7.
Chia S, Norris B, Speers C, et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol. 2008;26(35):5697-704. DOI: 10.1200/jco.2007.15.8659
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. N Engl J Med. 2005;353(16):1659-72. DOI: 10.1056/NEJMoa052306
Lammers P, Criscitiello C, Curigliano G, Jacobs I. Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets. Pharmaceuticals. 2014;7(9):943-53. DOI: 10.3390/ph7090943
İçli F, Altundağ K, Akbulut H, et al. Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG). Breast Cancer. 2015;22(5):480-5. DOI: 10.1007/s12282-013-0506-y
Rakha EA, Martin S, Lee AHS, et al. The prognostic significance of lymphovascular invasion in invasive breast carcinoma. Cancer. 2012;118(15):3670-80. DOI: 10.1002/cncr.26711
Zhong Y-M, Tong F, Shen J. Lympho-vascular invasion impacts the prognosis in breast-conserving surgery: a systematic review and meta-analysis. BMC Cancer. 2022;22(1):102. DOI: 10.1186/s12885-022-09193-0
Duraker N, Caynak ZC, Türköz K. Perineural invasion has no prognostic value in patients with invasive breast carcinoma. Breast. 2006;15(5):629-34. DOI: 10.1016/j.breast.2005.12.003
Hosoya K, Wakahara M, Ikeda K, Umekita Y. Perineural Invasion Predicts Unfavorable Prognosis in Patients With Invasive Breast Cancer. Cancer Diagn Progn. 2023;3(2):208-14. DOI: 10.21873/cdp.10203
Kuhn E, Gambini D, Despini L, Asnaghi D, Runza L, Ferrero S. Updates on Lymphovascular Invasion in Breast Cancer. Biomedicines. 2023;11(3):968. DOI: 10.3390/biomedicines11030968
Allemani C, Sant M, Weir HK, et al. Breast cancer survival in the US and Europe: a CONCORD high-resolution study. Int J Cancer. 2013;132(5):1170-81. DOI: 10.1002/ijc.27725
Authors
Copyright (c) 2024 Archives of Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.